Share

Publication of 2022 EORTC Annual Report

This comprehensive report collects the most relevant and up-to-date information on EORTC’s activities demonstrating the continuous progress achieved in the field of clinical cancer research by our organisation.

The 2022 edition is a very special one, as last year marked a significant milestone for our organisation which celebrated its 60th anniversary. Today, EORTC is a well-renowned independent, academic and multidisciplinary clinical cancer research organisation, whose network encompasses over 3,400 collaborators from diverse disciplines across more than 50 countries. 22,000 patients continue to be followed on a yearly basis and the EORTC clinical study database now contains outcome data for over 210,000 cancer patients.

As well, EORTC contributes actively to the evolving eco-systems in oncology whether addressing methodological, scientific or regulatory challenges. EORTC remains also very active in education for clinical research-related science.

This year we celebrate our past, but we also recognise the importance of continually evolving and adapting to meet future challenges and keep building on our distinguished record of scientific achievements.
– Dr. Denis Lacombe, EORTC CEO.

On behalf of EORTC, we would like to express our sincere gratitude to all the people who support, collaborate, and believe in the mission of EORTC to improve the survival and quality of life of cancer patients. 

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023